Clinical trials: Carcinoma, Transitional Cell
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma
Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)
Background: In European Association of Urology (EAU) Guidelines, the vast majority of non-muscle-invasive bladder cancers (NMIBCs) undergo a primary transurethral resection of the bladder tumor (TURBT) followed by a repeat TURBT…
- Conditions
- Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma, High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
- Trial name
- CUT-less (NCT05962541)
- Testing
- PDD-TURBT with hexaminolevulinate (Hexvix®), Power Led Saphira (TM)
- Where
- Italy
- Volunteers
- 327 people
- Sponsor
- University of Roma La Sapienza
Bladder Cancer
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
Primary Objective: 1. To compare the proportion of patients free from progression 9 months from the start of consolidation therapy with the combination of docetaxel and ZD1839 (Iressa) versus docetaxel alone.
- Trial name
- NCT00479089
- Testing
- Docetaxel, ZD1839, Dexamethasone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT00981656
- Testing
- cisplatin, 5-fluorouracil, Mitomycin
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Radiation Therapy Oncology Group
Bladder (Urothelial, Transitional Cell) Cancer, Non Muscle Invasive Bladder Cancer
Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
Patients with extensive transurethrally unresectable very-high-risk non-muscle-invasive bladder cancer (NMIBC) may achieve a tumor-free status after systemic immunotherapy-based bladder-sparing treatment combined with…
- Trial name
- NCT07625527
- Testing
- Active Surveillance, PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy
- Where
- 4 sites in China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Second Hospital
Upper Urinary Tract Urothelial Carcinoma
HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC
This is a prospective, single-center, single-arm phase II study evaluating whether a single postoperative intravesical instillation of disitamab vedotin (RC48) can reduce bladder recurrence after radical nephroureterectomy (RNU)…
- Trial name
- HERO-UTUC (NCT07591805)
- Testing
- Drug: Disitamab Vedotin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- RenJi Hospital
Urothelial Carcinoma, Bladder Cancer
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
This study evaluates the post cystectomy CD8+ tumor response of patients receiving Nivolumab plus Urelumab versus Nivolumab alone.
- Trial name
- NCT02845323
- Testing
- Nivolumab in combination with Urelumab, Nivolumab monotherapy
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Locally Advanced or Metastatic Urothelial Carcinoma
A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma
The study is being conducted to evaluate the efficacy and safety of Toripalimab Injection in combination with chemotherapy compared to placebo in combination with chemotherapy in subjects with PD-L1-positive unresectable locally…
- Trial name
- NCT04568304
- Testing
- Toripalimab Injection, Gemcitabine Hydrochloride for Injection, Cisplatin for Injection / Carboplatin Injection
- Where
- 3 sites in China
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Urothelial Carcinoma
JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study
This study is a multicenter, non-interventional, retrospective, medical chart review of locally advanced or metastatic (la/m) Urothelial Cancer UC participants who were prescribed avelumab as first line maintenance therapy after…
- Trial name
- NCT06412848
- Testing
- Avelumab
- Where
- 26 sites in Japan
- Volunteers
- 360 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Low-grade Upper Tract Urothelial Carcinoma
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects.
- Trial name
- LUNAR (NCT06668493)
- Testing
- Nadofaragene Firadenovec
- Where
- 9 sites in United States, France
- Volunteers
- 20 people
- Sponsor
- Ferring Pharmaceuticals
Infiltrating Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
This pilot clinical trial studies the side effects of recombinant EphB4-HSA fusion protein before surgery in treating patients with transitional cell carcinoma of the bladder, prostate cancer, or kidney cancer.
- Conditions
- Infiltrating Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage I Prostate Cancer, Stage I Renal Cell Cancer
- Trial name
- NCT02767921
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Radical Cystectomy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Southern California
Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer
This phase II trial studies how well pemetrexed and avelumab work in treating patients with MTAP-deficient urothelial cancer that has spread to other places in the body.
- Conditions
- Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant
- Trial name
- NCT03744793
- Testing
- Avelumab, Pemetrexed
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer
High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of high-dose multivitamins may be an effective way to prevent the recurrence of early stage bladder…
- Trial name
- NCT00003623
- Testing
- multivitamin
- Where
- 17 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Urinary Bladder Cancer
PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer
The primary objective of the study is to assess the efficacy of the combination consisting of gemcitabine/cisplatin and panitumumab in patients with urothelial carcinoma and wild-type HRAS (non-mutated status).
- Trial name
- PURO (NCT01374789)
- Testing
- GemCis + Panitumumab, GemCis
- Where
- 20 sites in Germany
- Volunteers
- 2 people
- Sponsor
- WiSP Wissenschaftlicher Service Pharma GmbH
Prostate Cancer, Oligoprogressive
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective.
- Conditions
- Prostate Cancer, Oligoprogressive, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- LAYOVER (NCT06101290)
- Testing
- Ablative local therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, Davis
Urinary Bladder Cancer, Upper Tract Urothelial Cancer
SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma
This Phase II clinical trial, titled "A Phase II Trial of Sequential Gemcitabine and Mitomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma (SUMMIT)," aims to evaluate the safety and effectiveness of…
- Conditions
- Urinary Bladder Cancer, Upper Tract Urothelial Cancer, Urothelial Cancer
- Trial name
- NCT06822010
- Testing
- Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Rutgers, The State University of New Jersey
Advanced Urothelial Carcinoma
Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma
In their "Magrolimab" research project, the investigators want to find out whether the new drug Magrolimab in combination with conventional chemotherapy is well tolerated and whether survival or progression-free survival improves.
- Trial name
- MACOCUC-01 (NCT05738161)
- Testing
- Magrolimab, Cisplatin, Gemcitabine
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Bladder Cancer, Urothelial Carcinoma Bladder
Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases
The goal of this observational study is to learn about the performance of the Bladder CARE™ Assay in patients suspected of having bladder cancer with atypical cytology or equivocal cystoscopy results.
- Trial name
- NCT06870253
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Pangea Laboratory LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.